TransMedics Group, Inc. (NASDAQ:TMDX) Given Average Rating of "Moderate Buy" by Brokerages

Shares of TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) have been assigned an average rating of "Moderate Buy" from the seven brokerages that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $102.00.

Several equities research analysts have recently commented on the stock. Piper Sandler assumed coverage on shares of TransMedics Group in a research report on Thursday, March 28th. They set an "overweight" rating and a $95.00 price target for the company. Morgan Stanley lifted their price target on shares of TransMedics Group from $75.00 to $95.00 and gave the stock an "equal weight" rating in a research report on Wednesday, February 28th. Oppenheimer lifted their price target on shares of TransMedics Group from $92.00 to $105.00 and gave the stock an "outperform" rating in a research report on Tuesday, February 27th. Finally, JPMorgan Chase & Co. lifted their price target on shares of TransMedics Group from $87.00 to $105.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 27th.

TransMedics Group Trading Down 0.7 %

TMDX traded down $0.62 during midday trading on Thursday, hitting $87.24. The company had a trading volume of 692,313 shares, compared to its average volume of 688,977. The company has a current ratio of 9.30, a quick ratio of 8.49 and a debt-to-equity ratio of 3.69. TransMedics Group has a twelve month low of $36.42 and a twelve month high of $99.63. The firm's 50-day simple moving average is $83.01 and its 200-day simple moving average is $72.88.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its quarterly earnings data on Monday, February 26th. The company reported $0.12 earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.22. The firm had revenue of $81.20 million during the quarter, compared to analysts' expectations of $68.49 million. TransMedics Group had a negative net margin of 10.36% and a negative return on equity of 2.35%. The company's quarterly revenue was up 158.6% compared to the same quarter last year. During the same quarter last year, the company posted ($0.21) EPS. On average, analysts forecast that TransMedics Group will post -0.14 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Tamer I. Khayal sold 2,330 shares of TransMedics Group stock in a transaction that occurred on Tuesday, January 23rd. The shares were sold at an average price of $90.09, for a total transaction of $209,909.70. Following the transaction, the insider now owns 14,375 shares of the company's stock, valued at approximately $1,295,043.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other TransMedics Group news, CEO Waleed H. Hassanein sold 12,000 shares of TransMedics Group stock in a transaction that occurred on Wednesday, April 10th. The shares were sold at an average price of $95.09, for a total value of $1,141,080.00. Following the transaction, the chief executive officer now owns 74,087 shares of the company's stock, valued at $7,044,932.83. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Tamer I. Khayal sold 2,330 shares of TransMedics Group stock in a transaction that occurred on Tuesday, January 23rd. The shares were sold at an average price of $90.09, for a total transaction of $209,909.70. Following the completion of the transaction, the insider now directly owns 14,375 shares in the company, valued at approximately $1,295,043.75. The disclosure for this sale can be found here. Insiders have sold 119,408 shares of company stock valued at $10,182,881 in the last 90 days. 6.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. Harbour Capital Advisors LLC lifted its stake in TransMedics Group by 1.7% in the fourth quarter. Harbour Capital Advisors LLC now owns 8,371 shares of the company's stock valued at $627,000 after buying an additional 140 shares in the last quarter. First Horizon Advisors Inc. lifted its position in shares of TransMedics Group by 45.1% in the first quarter. First Horizon Advisors Inc. now owns 544 shares of the company's stock worth $41,000 after purchasing an additional 169 shares in the last quarter. Belpointe Asset Management LLC lifted its position in shares of TransMedics Group by 51.6% in the first quarter. Belpointe Asset Management LLC now owns 558 shares of the company's stock worth $42,000 after purchasing an additional 190 shares in the last quarter. RiverPark Advisors LLC lifted its position in shares of TransMedics Group by 19.5% in the fourth quarter. RiverPark Advisors LLC now owns 1,319 shares of the company's stock worth $104,000 after purchasing an additional 215 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its position in shares of TransMedics Group by 2.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 14,512 shares of the company's stock worth $896,000 after purchasing an additional 288 shares in the last quarter. Institutional investors own 99.67% of the company's stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.